An interventional study of Lidocaine hydrochloride 2% for injection and 0.9% sterile Sodium Chloride solution for injection in Colorectal Cancer, Quality of Life and Recurrent Cancer, sponsored by Imperial College London. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing lidocaine in Colorectal Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Lidocaine · Colorectal Neoplasms.
Among the 13 studies testing lidocaine in Colorectal Neoplasms, this one is the 10th largest by planned enrollment, is one of 4 that started in 2023, is one of 7 with no phase, and was the 9th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →3 of the 13 studies testing lidocaine in Colorectal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 60+
Ciusss de L'Est de l'Île de Montréal · Sites in Canada
Ages 18+
By country, each count listing its studies:
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 1 · Phase 4 2
First in 2005; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 77 across the 13 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
13 studies in Colorectal Neoplasms by Imperial College London: 6 open now, 6 under way, none of them phase 3. Of 6 finished, 3 (50%) have results posted.
Among the 13 studies in Colorectal Neoplasms by Imperial College London, this one is one of 2 that started in 2023, is one of 4 with no phase, and was the 10th registered.
Imperial College London’s Colorectal Neoplasms studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing lidocaine in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Imperial College London’s 13 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This feasibility (small) study aims to see if it is possible to run a large study looking at the effect of lidocaine on large bowel cancer recurrence after surgery in the NHS hospitals.
Strong preclinical evidence suggests that lidocaine, a type of local anaesthetic commonly used, could potentially reduce cancer recurrence if given during cancer surgery. This study will evaluate the feasibility of conducting a study comparing intravenous lidocaine infusion versus placebo administration for 24 hours from the start of general anaesthesia. The specific population will be any stage 2 or 3 colon or rectal cancer patient undergoing elective laparoscopic colorectal cancer surgery to look at postoperative cancer outcomes in two NHS settings. This study will explore the acceptability, facilitators and potential barriers of recruiting cancer patients, with possible anxieties of a new cancer diagnosis about to have major surgery along with other potential feasibility issues. It will also assess if follow-up and outcome data collection can be streamlined with usual care processes as much as possible and to guide the future definitive trial.
The project will:
Perform a feasibility study. This will be similar in design to the future bigger study and will see:
The study will involve a small number of patients getting either lidocaine or placebo, and:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who are likely to have adverse effects from the accumulation of intravenous lidocaine:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
Drug: Lidocaine hydrochloride 2% for injection
An equivalent infusion rate (ml) of placebo will be administered following the induction of anaesthesia over 20 minutes followed by hourly equivalent intravenous infusion in ml/hr of placebo with a maximum rate of 6mls/hr (equivalent of 120mg/hour for lidocaine) for 24 hours.
Drug: 0.9% sterile Sodium Chloride solution for injection
An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
Also known as: Xylocaine
Administered as lidocaine
Also known as: Saline
Feasibility of recruitment
The number of eligible patients and the actual number recruited for colon and rectal cancer with stage 2 or 3.
Time frame: Baseline
Trial retention
The number of participants who consent to participate who remain in the study until the end of follow up at 12 months.
Time frame: 12 months post randomisation
The completion of data collection instruments
on eCRF
Time frame: 6 months post randomisation
The completion of data collection instruments
on eCRF
Time frame: 12 months post randomisation
Participant's feedback of study experiences
10 questions close-ended questionnaire with optional free text relating to informed consent procedures, the information given, the recruitment process and any suggestions for improvement.
Time frame: Day 3 hospital stay
Clinical staff feedback of study experiences
10 questions close-ended questionnaire with optional free text relating to informed consent procedures, the information given, the recruitment process and any suggestions for improvement.
Time frame: Day 3 hospital stay
Patients' reasons to refuse consent.
Patients who refuse consent will be asked for their reasons at the point of recruitment only
Time frame: Baseline
Clinicians' reasons for not recruiting patients.
Clinicians will be asked their reasons for not recruiting patients
Time frame: Screening
Disease-free survival
Cancer recurrence and death from any cause
Time frame: 12-months post randomisation
Completion of EQ-5D-5L
The completeness of responses to the health-related quality of life questionnaire, EQ- 5D-5L which would be the outcome measure used in an economic evaluation as part of the definitive trial.
Time frame: Baseline
Completion of EQ-5D-5L
The completeness of responses to the health-related quality of life questionnaire, EQ- 5D-5L which would be the outcome measure used in an economic evaluation as part of the definitive trial.
Time frame: 6 months post randomisation
Completion of EQ-5D-5L
The completeness of responses to the health-related quality of life questionnaire, EQ- 5D-5L which would be the outcome measure used in an economic evaluation as part of the definitive trial.
Time frame: 12-months post randomisation
Completion of the cancer-specific quality of life questionnaires
Feasibility and completion of the Cancer-specific quality of life measured using the Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire.
Time frame: Baseline
Completion of the cancer-specific quality of life questionnaires
Feasibility and completion of the Cancer-specific quality of life measured using the Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire.
Time frame: 6 months post randomisation
Completion of the cancer-specific quality of life questionnaires
Feasibility and completion of the Cancer-specific quality of life measured using the Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire.
Time frame: 12-months post randomisation
Completion of healthcare and social care resource use questionnaires
This will be a bespoke patient questionnaire on primary and secondary healthcare and social care resource use.
Time frame: 6 months post randomisation
Completion of healthcare and social care resource use questionnaires
This will be a bespoke patient questionnaire on primary and secondary healthcare and social care resource use.
Time frame: 12-months post randomisation
Total hospital stays including readmission
Recorded from medical notes and healthcare resource use form.
Time frame: 12-months post randomisation
Quantity of circulating free DNA
Change from baseline quantity of circulating free DNA at treatment completion
Time frame: Day 3 hospital stay
DNA whole-genome sequencing
Quantitative genomic analysis of the blood cells to study the characteristics and investigate the technical feasibility of this for the future definitive trial.
Time frame: Day 3 hospital stay
Quantity of circulating tumour cells
Change from baseline circulating tumour cells quantity at treatment completion
Time frame: Day 3 hospital stay
Circulating tumour cells functional characteristics
Comparison between lidocaine and placebo treatment group
Time frame: Day 3 hospital stay
Pro-inflammatory cytokine levels
Change from baseline pro-inflammatory cytokine levels at treatment completion
Time frame: Day 3 hospital stay
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Sep 2024, 19 months after the start.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 19 months is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine